RESUMEN
BACKGROUND: Injectable fillers such as poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA) have shown promising results in the treatment of combination antiretroviral therapy (cART)-induced facial lipoatrophy (FLA). However, the effects of these substances on magnetic resonance imaging (MRI) have not yet been described. OBJECTIVE: The authors analyze the association between the effects of treatment with semipermanent fillers on MRI and changes in quality of life (QOL). METHODS: Eighty-two human immunodeficiency virus (HIV)-positive patients with cART-induced FLA (grades 2-4) were enrolled in this prospective study. A mean volume of 58.2 mL (range, 12-105 mL) of PLLA (n = 41 patients) and 9.1 mL (range, 3-23 mL) of CaHA (n = 41) was injected in multiple sessions. The MRI examinations were performed prior to treatment and again 12 months after. The self-reported severity of FLA as well as QOL was measured using questionnaires based on Short Form 36, Medical Outcomes Study HIV Health Survey, and Center for Epidemiologic Studies Depression Scale formats. RESULTS: Significant increases in total subcutaneous thickness (TST) of the injected regions could be identified on MRI in nearly all patients 1 year posttreatment. Patients reported that mental health and social and role functioning improved; depressive symptoms decreased after treatment. In addition, the increase in TST was positively associated with improvement of QOL. CONCLUSIONS: This study confirms that treatment with both PLLA and CaHA not only increases TST but also is associated with improved QOL for HIV-infected patients. Furthermore, the study also demonstrates that MRI can show filler-induced neocollagenesis and quantify FLA treatment effects.
Asunto(s)
Materiales Biocompatibles/administración & dosificación , Técnicas Cosméticas , Durapatita/administración & dosificación , Seropositividad para VIH , Síndrome de Lipodistrofia Asociada a VIH/terapia , Ácido Láctico/administración & dosificación , Imagen por Resonancia Magnética , Polímeros/administración & dosificación , Calidad de Vida , Grasa Subcutánea/patología , Adulto , Anciano , Materiales Biocompatibles/efectos adversos , Técnicas Cosméticas/efectos adversos , Durapatita/efectos adversos , Cara , Femenino , Síndrome de Lipodistrofia Asociada a VIH/diagnóstico , Síndrome de Lipodistrofia Asociada a VIH/psicología , Síndrome de Lipodistrofia Asociada a VIH/virología , Humanos , Inyecciones Subcutáneas , Ácido Láctico/efectos adversos , Masculino , Persona de Mediana Edad , Poliésteres , Polímeros/efectos adversos , Valor Predictivo de las Pruebas , Estudios Prospectivos , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate factors influencing the onset and type of adverse events in patients injected with permanent fillers in the face and to propose a therapeutic strategy for these complications. METHODS: A prospectively attained series of 85 patients with delayed-onset complications after facial injection with permanent fillers underwent clinical follow-up and treatment of the complications. RESULTS: Lag times until onset and type of delayed-onset complication varied according to filler material. In 28% (n = 24) of the cases, patients reported the onset of complications after dental procedures, additional injections with fillers, or other invasive treatments in the facial area. Forty-eight (57%) patients required invasive treatment. Abscess formation was significantly more frequent in patients with human immunodeficiency virus infection and facial lipoatrophy (p = .001). CONCLUSION: The intrinsic characteristics of the injected filler and the immune status of the patient play important roles in the diversity of time of onset and type of delayed-onset adverse events observed. It seems that invasive facial or oral procedures in the vicinity of filler depots can provoke such complications. We propose a strategy for treating these complications and advise great caution when using permanent filling agents.
Asunto(s)
Absceso/inducido químicamente , Tejido Adiposo/patología , Técnicas Cosméticas/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Absceso/microbiología , Absceso/cirugía , Acrilatos/efectos adversos , Resinas Acrílicas/efectos adversos , Adulto , Anciano , Antirretrovirales/efectos adversos , Atrofia/inducido químicamente , Atrofia/tratamiento farmacológico , Colágeno/efectos adversos , Dimetilpolisiloxanos/efectos adversos , Cara , Femenino , Humanos , Ácido Hialurónico/efectos adversos , Hidrogeles/efectos adversos , Inflamación/inducido químicamente , Masculino , Persona de Mediana Edad , Polimetil Metacrilato/efectos adversos , Estudios Prospectivos , Rejuvenecimiento , Factores de TiempoAsunto(s)
Resinas Acrílicas/administración & dosificación , Técnicas Cosméticas/efectos adversos , Pene/cirugía , Prótesis e Implantes/efectos adversos , Escroto/cirugía , Aceites de Silicona/efectos adversos , Resinas Acrílicas/efectos adversos , Adulto , Edema/inducido químicamente , Cuerpos Extraños , Humanos , Hidrogeles , Inyecciones , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Implantación de Prótesis/efectos adversos , Aceites de Silicona/administración & dosificación , Trasplante de Piel , Cicatrización de HeridasRESUMEN
BACKGROUND: Highly active antiretroviral therapy (HAART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients. We assessed the long-term effects of polyalkylimide gel injections on the severity of lipoatrophy and quality of life of patients on HAART. METHODS: A prospective study was performed of 17 HIV-positive patients with grade 2 and grade 3 facial lipoatrophy. A mean volume of 14 cc of polyalkylimide gel (Bio-Alcamid) was injected subcutaneously at one or more sites of the face in a single stage. Each patient was seen for follow-up after 3, 12, 24, and 48 weeks. The severity of lipoatrophy and the quality of life was assessed using a self-report questionnaire containing the relevant parts of the SF-36, MOS-HIV, and CES-D. RESULTS: The severity of facial lipoatrophy decreased significantly from baseline over 48 weeks. Quality of life improved significantly from baseline over 48 weeks for mental health and social functioning. Depression at week 48 was significantly correlated with the extent to which lipoatrophy had disappeared at week 48. CONCLUSION: Individualized volumes of polyalkylimide gel injected in one session significantly decreased the subjective severity of lipoatrophy and improved the quality of life of HIV-positive patients with grade 2 and 3 lipoatrophy, even in the four patients who had complications.